Fused indazole pyridone compounds as antivirals

A compound of formula (I):

• wherein:
• R1 is H or halo;
• R2 is independently selected at each occurrence from halo, CN, C1-C3 haloalkyl, C1-C3 haloalkoxy, —OR3, —N(R)R3, and C1-C3 alkyl optionally substituted with up to three groups selected from R3, —N(R)R3, CN, —OH, —CONR2, —COOR, and —OR3;
• R3 is a C1-C4 alkyl that is optionally substituted with one to three groups selected from halo, C1-C3 haloalkyl, —OH, C1-C3 alkoxy, C1-C3 haloalkoxy, oxo, CN, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —COOR, —CONR2, C3-C5 cycloalkyl, and a 4-6 membered cyclic ether, wherein the C3-C5 cycloalkyl and 4-6 membered cyclic ether are each optionally substituted with one or two groups selected from halo, —OH, C1-C3 alkoxy, and C1-C3 alkyl;
• or R3 is a C3-C5 cycloalkyl ring or 4-6 membered cyclic ether, wherein the C3-C5 cycloalkyl ring or 4-6 membered cyclic ether are each optionally substituted with one to three groups selected from halo, C1-C3 alkyl, —OH, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 haloalkyl, —NH2, —NH(C1-C3 alkyl), and —N(C1-C3 alkyl)2;
• n is 0, 1, or 2;
• W is —COOR4, —C(O)NH-—SO2R5, —C(O)NH—SO2NR2, 5-tetrazolyl, or 1,2,4-oxadiazol-3-yl-5 (4H)-one;
• R4 is H or C1-C6 alkyl that is optionally substituted with one to three groups selected from halo, —OR, oxo, CN, and —NR2;
• R5 is C1-C6 alkyl that is optionally substituted with one to three groups selected from halo, —OR, oxo, CN, and —NR2;
• R6 is H or C1-C6 alkyl;
• R7 is H or C1-C6 alkyl,
• or R7 taken together with R9 and the atoms connecting R7 with R9 forms a ring as described below;
• R8 is H or C1-C6 alkyl;
• R9 is selected from:
• (1) H;
• (2) C1-C6 alkyl optionally substituted with up to three groups selected from C3-C6 cycloalkyl, —OR, —NR2, halo, CN, COOR, CONR2, and oxo;
• and
• (3) a ring selected from (a) C3-C6 cycloalkyl, (b) phenyl, (c) 5-6 membered heterocyclyl containing one or two heteroatoms selected from N, O and S as ring members, and (d) 5-6 membered heteroaryl containing one or two heteroatoms selected from N, O and S as ring members, wherein each of rings (a) through (d) is optionally substituted with up to three groups selected from C1-C2 alkyl, (CH2)0-2—OR, —NR2, halo, CN, COOR, and CONR2;
• or R9 taken together with R7 and the atoms connecting R9 with R7 forms a 3-7 membered cycloalkyl ring, or a 3-7 membered heterocyclic ring containing N, O or S as a ring member;
• wherein the cycloalkyl or heterocyclic ring is optionally substituted with up to three groups selected from R, —OR, —NR2, halo, CN, COOR, CONR2, and oxo;
• R is independently selected at each occurrence from H and C1-C3 alkyl optionally substituted with one to three groups selected from halo, —OH, C1-C3 alkoxy, oxo, CN, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, and cyclopropyl;
• and two R groups directly attached to the same atom can optionally be taken together with the atom to which both are attached to form a 3-6 membered ring that can optionally contain a heteroatom selected from N, O and S as a ring member, and can be substituted by up to two groups selected from —OH, oxo, C1-C3 alkyl, and C1-C3 alkoxy;
• or a pharmaceutically acceptable salt thereof.